Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;9(1):1-5.
doi: 10.1016/j.prnil.2020.03.002. Epub 2020 Mar 31.

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Emre Yekedüz  1 , Güngör Utkan  1 , Ravindran Kanesvaran  2 , Yüksel Ürün  1
Affiliations
Review

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Emre Yekedüz et al. Prostate Int. 2021 Mar.

Abstract

Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance to androgen deprivation therapy is inevitable. After using enzalutamide, the first new generation anti-androgen (AA), two new generation AA drugs were synthesized. New generation anti-androgen drugs are used especially in castration resistance prostate cancer. But recently, there are new publications regarding using new generation anti-androgens in castration sensitive prostate cancer patients. In this review, we will compare structure, mechanisms of effect and clinical outcomes in phase 3 trials of these new generation AA drugs.

Keywords: Androgen Receptor Antagonists; Androgen-Resistant Prostatic Cancer; Prostatic Neoplasms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of action of the new generation antiandrogens.
Figure 2
Figure 2
Journey of NSAAs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bravaccini S., Puccetti M., Bocchini M., Ravaioli S., Celli M., Scarpi E. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci Rep. 2018;8:4254. - PMC - PubMed
    1. Handy C.E., Antonarakis E.S. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907–917. - PMC - PubMed
    1. Wang D., Tindall D.J. Androgen action during prostate carcinogenesis. Methods Mol Biol. 2011;776:25–44. - PubMed
    1. Huang Y., Jiang X., Liang X., Jiang G. Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett. 2018;15:6063–6076. - PMC - PubMed
    1. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790. - PMC - PubMed

LinkOut - more resources